Marino Garcia is the CEO of Dianthus Therapeutics, appointed in September 2023, following a significant transition in company leadership. He has a solid foundation in business with an M.B.A from Ivey Business School and a Bachelor of Commerce from Concordia University. His career spans various roles within the biopharmaceutical industry, with notable positions at Zealand Pharma, Synergy Pharmaceuticals, and Aptalis Pharma. Garcia’s strategic vision focuses on drug development and clinical trial preparedness, which aligns with Dianthus's current goals. In 2023, his compensation included a base salary of $174,863 and a bonus of $321,159, reflecting his performance-driven approach. Additionally, he recently became a board member and will serve until the company’s 2025 annual meeting. His leadership comes at a time when the company aims to innovate significantly in its clinical pipeline. Garcia’s diverse experience and expertise in business development bring a solid perspective as Dianthus navigates its goals.

Dianthus TherapeuticsSeptember 2023 - September 2023

Current Market Cap

$852.90M

Number of Employees

Total Compensation

2023 - 2023

Trending up by 0.00% last year

Showing total compensation for the last 2023 - 2023

Stock

Up by 0.00% last year

Salary

Up by 0.00% last year

Bonus

Up by 0.00% last year

Other

Up by 0.00% last year

2023

Year

2023

Total Compensation

$496.02K

Salary

$174.86K

Board Justification

The compensation philosophy focuses on aligning executive compensation with company performance, peer benchmarking, and retention strategies, aiming to motivate executives to achieve short- and long-term results in the best interests of stockholders.

Bonus

$321.16K

Board Justification

The bonus is based on the annual cash incentive payouts earned for performance in 2023, which are expected to be paid in February 2024. The annual incentive program was based on achievement of corporate performance goals related to clinical trial readiness and pipeline development, with payouts approved at 115% of target.

Other

$0.00

Board Justification

No other compensation was reported for 2023.

Restricted Stock

$0.00(0 common stock)

Board Justification

No stock was reported as vested in 2023.

Performance Metrics

The performance metrics for determining compensation in 2023 included execution towards organizational readiness for clinical trials and pipeline development.

SEC Filing

From April 11, 2024

View SEC Filing

Marino Garcia

Ex-CEO of Dianthus Therapeutics

Education

M.B.A. from Ivey Business School, Western University; Bachelor of Commerce from Concordia University.

Field of Expertise

Business & Management

Born

January 1, 1967 - 57 years ago

Is Founder?

Tenure

0 years 0 months (Sep 2023 - Sep 2023)

Previous Experience

President and Chief Executive Officer of OpCo; Senior Vice President, Corporate and Business Development at Zealand Pharma; Executive Vice President, Chief Strategy Officer at Synergy Pharmaceuticals; Vice President, US Commercial Operations and Global New Product Development at Aspreva; various roles at Merck, Pfizer, and Eli Lilly.

View Holdings

Insider Holdings of Marino Garcia

DNTH

$7.07M

$1.68M (31.23%)